Pathogen Reduced Cryoprecipitated Fibrinogen Complex + Cryoprecipitated-Antihemophilic Factor
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypofibrinogenemia
Conditions
Hypofibrinogenemia, Hemorrhage
Trial Timeline
May 1, 2026 → Aug 1, 2028
NCT ID
NCT07218185About Pathogen Reduced Cryoprecipitated Fibrinogen Complex + Cryoprecipitated-Antihemophilic Factor
Pathogen Reduced Cryoprecipitated Fibrinogen Complex + Cryoprecipitated-Antihemophilic Factor is a pre-clinical stage product being developed by Cerus for Hypofibrinogenemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07218185. Target conditions include Hypofibrinogenemia, Hemorrhage.
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07218185 | Pre-clinical | Recruiting |
Competing Products
1 competing product in Hypofibrinogenemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Traditional Cryoprecipitate + Pathogen-Reduced Cryoprecipitate | Cerus | Approved | 77 |
Other Products from Cerus
Traditional Cryoprecipitate + Pathogen-Reduced CryoprecipitateApproved
77
Pathogen-Reduced Plasma + Crystalloid SolutionsApproved
77
S-303 Treated Red Blood Cells (RBCs) + Conventional, untreated Red Blood CellsPhase 3
69
S-303 Red Blood Cells (RBCs) - Test + Conventional, untreated red blood cells (RBCs) - ControlPhase 3
69
Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets. + Autologous apheresis Conventional untreated Platelet ComponentsPhase 2
44